Business, Free News Articles, Regional Events, Surgery and Neurotechnology

Emerging Neurotechnology Startups to Present at 2023 Neurotech Leaders Forum in San Francisco

SAN FRANCISCO, Calif. -- Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that several promising neurotechnology startups and early-stage firms will present at the 2023 Neurotech Leaders Forum in San Francisco, November 6-7. The 23rd annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Among the new and emerging neurotech firms presenting at the conference are Opto Biosystems, a U.K. developer of novel diagnostics for brain cancer, NeuraLace Medical, a San Diego-based manufacturer of noninvasive therapies for treating chronic pain, Spark Biomedical, a Texas firm developing noninvasive therapies for treating addiction, and Harmonic Pain Solutions, an Atlanta, GA-area developer of wearable pain devices that use mechanical stimulation.

Jim Schuermann, president and CEO of Saluda Medical, will deliver the keynote address on the morning of November 6. He will speak on the topic "New Directions in Neuromodulation."

Daniel Kraft, founder of NextMed Health, chair of medicine for Singularity University, and chair of the XPrize Pandemic & Health Alliance, will deliver a keynote address on November 7 devoted to the topic, "The Future of Health and Medicine: Where Can Technology Take Us?" Kraft is board certified in internal medicine and pediatrics and completed fellowships in hematology/oncology and bone marrow transplantation at Stanford. He has given six TED & TEDMED talks.

Another featured presenter will be Prasad Shirvalkar, an associate professor at UC San Francisco School of Medicine, who recently co-authored a seminal paper relating to pain biomarkers. Chris Rozell, a professor at Georgia Tech, who recently coauthored a paper on biomarkers for depression, will also make a presentation at the event.

Neurotech Reports senior contributing editor JoJo Platt will moderate a panel titled "Neurotech Investment: Bouncing Back from the Downturn," which will feature advice and recommendations from several venture capital professionals, including Sara Shnider from Joy Ventures, Martin Dieck from Neurotechnology Investors, and Suraj Mudichintala from Action Potential Venture Capital.

Neurotech Reports senior consulting editor Jeremy Koff will moderate a session titled "Changing Landscape: New SCS and PNS Vendors Enter the Scene," which will examine the current competitive environment in neuromodulation. Neurotech Reports editor James Cavuoto will moderate a session titled "Interpreting the Data: Neuromodulation Vendors Ward Off Negative Publications. And Neurotech Reports contributing editor Victor Pikov will moderate a session titled "Choosing Our Role Models: What Neurotech Can Learn from Other Healthcare Industries."

The Platinum Sponsor at this year's event is Cirtec Medical. Micro Systems Technology is the Gold Sponsor. Valtronic, Velentium, Focus, Neo-Bionica, and Iris Biomedical are Silver Sponsors, while TTP and Microdul are Bronze sponsors.

For more information on attending or sponsoring, contact Neurotech Reports at 415 546 1259 or visit this link: https://neurotechreports.com/pages/leadersforum.html

Related link: https://www.neurotechreports.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Education and Schools, Free News Articles, Surgery and Neurotechnology

Spine IEP Fellows & Young Surgeons’ Course Announces Premier Foundation Sponsor for its 2023 Course

SAN DIEGO, Calif. -- Magnifi Group, Inc., announced today its partnership with SI-BONE, Inc. as the Premier Foundation Sponsor for its 2023 Spine IEP Fellows & Young Surgeons' Course to be held in Atlanta, Georgia, November 17-19.

SI-BONE is a global leader in technology for the surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,000 surgeons in performing a total of over 80,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including two randomized controlled trials and over 120 peer-reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.

As a returning sponsor to the Spine IEP Course, SI-BONE is committed to advancing the field of spine surgery through innovation, education, and collaboration with leading medical professionals.

Geoff Maw, SI-BONE Vice President of US Academic & Commercial Development said SI-BONE has a long history of dedicating time and resources to the next generation of spine surgeons.

"The Spine IEP Fellows & Young Surgeons' Course is an ideal setting in which SI-BONE can further support the education of young surgeons," Maw said. "We look forward to taking a leading role in our commitment to this important course," Maw added.

"The Spine IEP Course for Fellows & Young Surgeons, now in its 13th consecutive year, continues to educate attendees on the latest medical device techniques and biologics," said Dr. Frank Phillips, Spine IEP Course Chair and Director, Department of Orthopedic Surgery, Rush University Medical Center. "SI Bone has been an active participant at the Spine IEP Course for many years and we welcome the company's sustained commitment to Spine Fellows & Young Surgeons," Phillips said.

The Spine IEP Fellows & Young Surgeons' Course, is limited to 50-55 attendees in order to accommodate a didactics rotation schedule of 45-50 tables hosted by medical device and biologics companies. Four cadaver labs will also be offered during the duration of the course.

The interactive course has been specifically developed to educate spine and neurosurgery Fellows and Young Surgeons on current topics related to the practice of spine and neurosurgery, as well as to assist attendees with the transition from academics to practicing surgeons. The classroom format for the course is highly interactive and all sessions conclude with question/answer sessions and panel discussions.

According to Magnifi data, an average of 70-80 spine Fellows enter the US market each year as practicing spine surgeons. Of these, 48-50 Fellows & Young Surgeons are expected to attend the upcoming course.

Magnifi Group, Inc. is a developer of an FDA-compliant eLearning platform for the medical device and biologics industries. The company also hosts the Spine IEP Live Fellows Course; the Lower Extremity IEP Live Fellows Course and the Hip and Knee IEP Live Fellows Course.

Learn more: https://www.magnifigroup.com/

Related link: https://www.magnifigroup.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Surgery and Neurotechnology

Helen Mayberg to Keynote 2023 Bioelectronic Medicine Forum in New York City

NEW YORK, N.Y. -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Sixth Annual Bioelectronic Medicine Forum will take place on April 4, 2023. The one-day event will be held at the New York Academy of Medicine in Manhattan.

The keynote speaker at this year's event is Helen Mayberg, Director of the Nash Family Center for Advanced Circuit Therapeutics at Mount Sinai School of Medicine. Mayberg is recognized as one of the pioneers of neuromodulation for treating psychiatric disorders. She will speak on the topic, "Pharmacological therapies simply aren't enough."

Other sessions will cover a range of technologies and indications for bioelectronic medicine, including applications in cardiovascular medicine, inflammation, gastrointestinal disorders, and many other clinical specialties. There will also be several informative panel discussions on key topics such as investment, emerging technologies, and reimbursement. Neurotech Reports editors James Cavuoto, Jeremy Koff, JoJo Platt, and Victor Pikov will moderate sessions at the event

The founders and CEOs of several promising bioelectronic medicine startups will also present at the conference. Entrepreneur presenters Brad Schmidt, CEO of Panaxium, which is developing a new "iontronic" brain interface, Marc Powell, CEO of Reach Neuro, which has developed a new stroke rehabilitation therapy, Luca Ravagnan, CEO of WISE srl, an Italian firm developing thin, stretchable brain electrodes, and Karen Crow, CEO of NeuroGeneces, which has developed a sleepband that performs brain health assessment using A.I. and EEG data.

Cirtec Medical is the Platinum Sponsor of the conference. MST is the Gold Sponsor and Valtronic and Velentium are Silver Sponsors.

"Bioelectronic medicine is one of the most promising new segments of the healthcare industry," said James Cavuoto, editor and publisher at Neurotech Reports. "This sixth-annual conference will be a key meeting place for entrepreneurs and executives helping to build this industry."

For more information on the 2023 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: https://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

Related link: https://www.neurotechreports.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Regional Events, Surgery and Neurotechnology

Twelve Neurotechnology Startups to Present at 2022 Neurotech Leaders Forum in San Francisco

SAN FRANCISCO, Calif. -- Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that 12 promising neurotechnology startups and early-stage firms will present at the 2022 Neurotech Leaders Forum in San Francisco, November 7-8. The 22nd annual event - the most established in the industry - will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Mudit Jain, Ph.D., general partner at VC firm Treo Ventures, will keynote the conference. Dr. Jain has more than two decades of medical device industry experience across company formation, R&D, business development, and venture capital, with a global perspective on healthcare based on his experiences in the U.S., Ireland, and India. He is the co-founder of NuXcel, a medical device accelerator, and also serves as chairman of the board of ShiraTronics Inc., a NuXcel spinoff. He received his Ph.D. in Biomedical Engineering from Duke University, and his M.B.A. from the Wharton School, University of Pennsylvania.

"The neurotechnology industry has emerged as one of the most promising areas of healthcare technology, and Neurotech Reports has been following the space longer than any other organization," said James Cavuoto, editor and publisher at Neurotech Reports. "This year's conference-our 22nd annual-will offer unique insights for management and investment professionals involved with the industry."

The agenda for this year's event includes panel discussions on a number of topics, including sessions devoted to reimbursement, securing funding, the new competitive landscape in neuromodulation, deep-brain stimulation, and neurorehabilitation. New this year is a session devoted to privacy, security, and ethics in neurotechnology.

Among the companies presenting this year are gBrain, a Korean manufacturer of graphene-based brain engineering systems, Motif Neurotech, a Texas developer of compact implanted brain stimulation devices for treating depression, and REVAI, a Canadian manufacturer of AI-powered vagus nerve stimulation systems for learning and wellness applications. Other presenting companies are Neural Dynamics Technologies, NeuroSigma, Roga Life, NXTStim, PathMaker Neurosystems, NeuronOff, WISE Srl, Sana Health, and Zeto Inc.

The Platinum Sponsor at this year's event is Cirtec Medical. Micro Systems Technology is the Gold Sponsor. Valtronic and MCRA are Silver Sponsors, and the Cleveland FES Center is Bronze Sponsor.

For more information on attending or sponsoring, contact Neurotech Reports at 415 546 1259 or visit this link: https://neurotechreports.com/pages/leadersforum.html.

Related link: https://www.neurotechreports.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Regional Events, Surgery and Neurotechnology

Key Entrepreneurs to Present at 2022 Bioelectronic Medicine Forum

NEW YORK, N.Y. -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that founders and CEOs of several promising bioelectronic medicine startups will present at the Fifth Annual Bioelectric Medicine Forum on April 5, 2022. The event will take place in New York City, although participation via Zoom videoconference will be accommodated.

Entrepreneur presenters at the conference include Attila Borbath, CEO of Synergia Medical, a European firm developing an optical vagus nerve stimulation system, Nicolas Vachicouras, CEO of Neurosoft Bioelectronics, Jennifer Ernst, CEO of Tivic Health, Manfred Franke, CEO of Neuronoff Inc., and Anuj Bhardwaj, CEO of SecondWave Systems Inc.

Peter Staats, a bioelectronic medicine pioneer and co-founder and chief medical officer of electroCore Medical, will keynote the conference. Dr. Staats is internationally recognized for his work in developing and implementing minimally invasive procedures for a number of disorders, including COVID, and his patents have led to the use of novel pharmacologic agents. He is a past President of the North American Neuromodulation Society, American Society of Interventional Pain Physicians, New Jersey Society of Interventional Pain Physicians, and the Southern Pain Society.

Other speakers at the 2022 event include Marom Biksom, professor of biomedical engineering at City College of New York, Imran Eba, partner at Action Potential Venture Capital, Chihiro Hosoya, head of venture management and business development at Astellas Pharma, Eric Hudak, program director at the National Institutes of Health, and Hannah Claridge from TTP plc in the U.K.

Other sessions will cover a range of technologies and indications for bioelectronic medicine, including applications in cardiovascular medicine, inflammation, gastrointestinal disorders, and many other clinical specialties.

MST is the Platinum Sponsor of this year's event, while Valtronic is the Silver Sponsor.

Key topics will include promising new indications, alliances with bio/pharm firms, regulatory and reimbursement issues, and pricing/commercialization issues.

"Bioelectronic medicine is one of the most promising new segments of the healthcare industry," said James Cavuoto, editor and publisher at Neurotech Reports. "This fifth-annual conference will be a key meeting place for entrepreneurs and executives helping to found this industry."

For more information on the 2022 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: https://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

RELATED LINKS:
https://www.neurotechreports.com/

Related link: http://www.neurotechreports.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Innobiochips (IBC), a developer of innovative immunoassays and the SirYus™ diagnostic platform technology, to develop personalized HLA diagnostics that will detect and quantify donor specific antibodies (DSA's) in post-transplant settings and provide the basis for post-transplant monitoring and early detections of transplant rejection.

The research is being led by Innobiochips co-founders Drs. Vianney Souplet and Christophe Olivier, and Dr. Rico Buchli, VP of Products and Services at PTS. The collaboration aims to develop and validate new individualized, allele specific HLA-antibody diagnostics. The initial goals of the collaboration are to quickly develop the first commercial prototype and gather the data needed to validate the platform with leading community experts. The companies are optimistic that they will be able to rapidly provide a new portfolio of allele specific diagnostics to HLA lab directors, transplant clinicians and transplant patients that do not currently exist. These new diagnostics would enable personalized, easy to use, and quantifiable sequential monitoring of patient specific DSA levels, the result of which would provide a new pro-active window for clinicians to implement earlier graft saving interventions for transplant recipients.

"Between our two companies, we feel that we already have the ingredients needed to provide a new set of tools to those who care for transplant patients," Dr. Buchli stated. "Our proteins solve a number of important challenges on the serological side while the Innobiochips SirYus platform provides a very easy to use and elegant way to manufacture discrete, allele specific tests with the necessary controls, it really is a powerful combination."

"Over the past years, our companies have been exploring ways to combine our complementary technologies to create breakthrough diagnostics in the transplant market. PTS has the in-depth knowledge in HLA proteins and IBC has demonstrated that its technology is incredibly flexible and can enable as many as 144 serological assays at the same time in a single well, providing the transplantation departments an outstanding and new solution for HLA detection," Dr Souplet stated.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation.

Learn more: https://www.puretransplant.com/

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Innobiochips

Innobiochips is a diagnostic company committed to provide innovative multiplex immunoassays and aims to position its technology, SirYus™, as a new standard for In Vitro Diagnostics. As of today, Innobiochips has developed and produces products dedicated to transplantation and immunodeficiency and is partnering with several major players to incorporate the SirYus technology into larger IVD applications.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens in Transplant Rejection

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Northwestern University, a world leader in HLA DQ antigen research.

The focus of the collaboration is to develop and test novel HLA reagents created by PTS that may be used for enhanced analysis and characterization of DQ antigens, an HLA Class II type that is increasingly gaining importance in causing rejection in transplant patients.

The research is being led by Dr. Anat Tambur, Director of the Transplant Immunology Laboratory and Comprehensive Transplant Center at Northwestern University Feinberg School of Medicine, and Dr. Rico Buchli, VP of Products and Services at PTS.

"The Tambur lab at the Comprehensive Transplant Center, Northwestern University, Chicago, is focusing on understanding the immunogenicity of HLA-DQ antigens and its role in antibody-mediated rejection in solid organ transplantation," said Dr. Tambur. "Increasing evidence has demonstrated that DQ mismatches between transplant recipient and donor are the most common to induce de novo donor-specific antibodies (DSA). HLA-DQ antibodies are likely also the most detrimental to graft survival. Understanding the unique structural and molecular properties that make the HLA-DQ molecule so pathogenic may eventually help us better predict which mismatches will induce harmful antibody formation, and which are more permissible. This work requires availability of purified HLA-DQ and other HLA class II molecules, maintaining high physiologic accuracy of the three-dimensional structure. Our collaboration with Pure Transplant Solutions allows us to develop unique approaches to study the unique involvement of HLA-DQ in transplant immunology."

"In the last years, we have seen a re-emerging role of HLA-DQ in transplantation medicine with increasing evidence that DQ mismatches between transplant recipient and donor are most detrimental to graft survival," said Dr. Buchli. "Our panel of highly representative HLA-DQ alleles will help to drive novel research to prevent transplant rejection and to contribute to more insight into DSA responses and we are thrilled to be working with Dr. Tambur, a world leader in this field."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients

BIRMINGHAM, Ala. -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research, to develop a new class of transplant diagnostics aimed at the detection and identification of HLA-specific memory B cells which are poised to produce HLA-specific immunoglobulin injurious to transplanted grafts.

The research is being led by Dr. Frances Lund, Charles H. McCauley Professor and Chair Department of Microbiology, Dr. John Killian, resident in the Department of Surgery, and Dr. Rico Buchli, VP of Products and Services at PTS, and focuses on using PTS's newly created Class I and Class II biotinylated soluble HLA (sHLA) proteins to understand the breadth and specificity of HLA-reactive B cells in sensitized individuals. These proprietary HLA molecules can be utilized in standard flow cytometry workflows for easy processing and analysis that the parties hope will provide a new tool for clinicians and researchers to use when caring for transplant patients.

Almost all previous work on HLA sensitized individuals has relied upon assays that detect circulating anti-HLA antibodies. The goal is to determine the reactivities of HLA-reactive B cells in these sensitized patients and compare these reactivities to those that are present among circulating anti-HLA antibodies. Using panels of biotinylated HLA molecules in combination with various tetramerized fluorescent reagents allows the interrogation of the specific B cell receptors expressed by HLA-reactive B cells.

"Prevention of B cell activation and proliferation is crucial for the survival of a transplant patient. For patient monitoring, identifying the right approach to immune profiling at each stage of clinical development-including the later stages, when it is often considered impractical to include these approaches-may be critical for identifying predictors of rejection responses, or monitoring immunosuppression efficacy", said Dr. Buchli. "Flow cytometric analysis using our fluorescent tagged HLA products have the capabilities needed to meet the increased demands to detect, identify, and monitor HLA-specific memory B cells."

"Our research at the University of Alabama at Birmingham seeks to improve the success of organ transplants," said John Killian, Jr., M.D., a research resident in the UAB Department of Surgery. "One problem is that following pregnancy or transplant, patients form antibodies against non-self HLA molecules. These antibodies comprise a major barrier to transplantation, and they exacerbate gender and racial disparities for thousands of people who await a life-saving transplant. Thus, we want to understand the breadth and specificity of HLA-reactive memory B cells in sensitized women. Pure Protein's extensive selection of recombinant HLA molecules will be integral to our projects, allowing us to pair fluorescence-activated cell sorting of HLA-reactive B cells with subsequent analysis of recombinant-antibody specificities. An improved understanding of the phenotype and specificity of HLA-reactive B cells will offer new opportunities to diagnose and treat HLA sensitization."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About the University of Alabama Birmingham

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham, a part of the University of Alabama System, is an internationally renowned research university and academic medical center with over $600 million in research awards annually, as well as Alabama's largest employer, with some 23,000 employees, and has an annual economic impact exceeding $7 billion on the state. The pillars of UAB's mission include education, research, innovation and economic development, community engagement, and patient care. Learn more at https://www.uab.edu/.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Defense and Military, Free News Articles, Surgery and Neurotechnology

‘Special Twins’ Tour of Duty Makes History

HOWELL, N.J. -- Mid-Atlantic Multi-Specialty Surgical Group, L.L.C. (MAMSURG) is announcing that two of their providers, Vince and Vance Moss, Army Reservists, Colonels, and G.H.O.S.T. surgeons for U.S. Special Operations Command, are returning home from Afghanistan in support of Operation Resolute Support following a unique, unprecedented 6 month tour of duty, making history by serving with the special forces as forward trauma surgeons, side by side.

Family members serving simultaneously in combat is rare, but even more uncommon is twins serving together in the same combat theater with the U.S. Special Operations. This rarity has become a reality. Twin brothers, Colonels Vince and Vance Moss (49 years old) have served on active duty together with the 909th General Hour Offset Surgical Team (G.H.O.S.T.), U.S. Special Operations Command in Afghanistan since January 2020. This act alone has not been known to be done on record. They had the unique experience of providing trauma surgery for the special forces during their missions. While serving, Vince's wife gave birth to his son, making this homecoming even more special when he meets him for the first time.

"It's been unbelievable serving with Vance in combat with so many talented warriors. I think it allowed me, once and for all, the opportunity to show my baby brother who's the better surgeon. I'm certainly looking forward to getting home and meeting my son for the first time and sharing that experience with my brother," said Vince Moss.

"It's been a great experience serving with the special forces environment with my brother at my side. I can't truly put into words how to describe the many reactions we received when people saw us. It was quite extraordinary. I'm looking forward to meeting my nephew for the first time," said Vance Moss.

The twins are originally from the Washington D.C. area. Penn State and Temple graduates, they are in private practice in New Jersey. The Moss brothers have been in the Army Reserves for over 15 years and served multiple tours in Iraq and Afghanistan. They have received many accolades for their work including being named ABC World News Tonight "Person(s) of the Year" and multiple invites to the White House.

The Moss brothers are scheduled to be returning home tentatively on June 30, 2020.

For more information, visit: https://www.mamsurg.com/.

About MAMSURG, L.L.C.:

Based in Howell, New Jersey, MAMSURG, L.L.C. is a surgical group of board-certified surgeons skilled in a variety of specialized techniques from renal transplantation, general surgery, urology and thoracic surgery. More importantly, their dedication to providing top notch, large center quality of care to the communities of New Jersey and the military is at the top of their agenda. The practice was started by Vince and Vance Moss in 2005 which the goal of focusing on underprivileged populations. For more information, visit: https://www.mamsurg.com/.

*PHOTO link for media: https://www.Send2Press.com/300dpi/20-07070s2p-Moss-Bros-2020-300dpi.jpg
*Photo caption: Surgeons/Colonels Vince (left) and Vance (right) Moss in an undisclosed location in Afghanistan with US Special Operations.

Related link: https://www.mamsurg.com

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Education and Schools, Free News Articles, Surgery and Neurotechnology

Record Early Enrollment for Lower Extremity Fellows, Residents & Young Surgeon 3rd Annual Course

SAN DIEGO, Calif. -- Magnifi Group, Inc. and Bespa Global, LLC, co-organizers of the program, announced today that despite the change of date for its 3rd Annual Lower Extremity IEP Fellows, Residents and Young Surgeons Course it is still experiencing record early registration. The course, originally scheduled for May 1-3 will take place from November 6-8, 2020 at The Omni Downtown, Austin, Texas.

This increased level of interest has been attributed to COVID-19 and the lack of in-person training opportunities for these young clinicians.

Lower Extremity IEP Program Co-chair, Dr. Donald R. Bohay, who serves as Professor Orthopaedic Surgery, Michigan State University and the Director of Grand Rapids Orthopedic Foot and Ankle Fellowship Program, said now more than ever, the prior and incoming class of Orthopedic Fellows and Final Year Podiatric Residents will significantly benefit from the Lower Extremity IEP Course.

"Given the current pandemic, these residents and fellows have not had the opportunity to participate in the usual array of cases, cadaver labs and in-person educational sessions," Dr. Bohay said. Dr. Bohay added that the impact is not limited to large COVID-19 cluster cities - it has impacted centers and schools across the country.

The Lower Extremity IEP Fellows, Residents & Young Surgeons' Course has been specifically developed to educate Fellows, Residents and Young Surgeons on current topics related to the practice of foot and ankle surgery, as well as to assist attendees with the transition from academics to practicing surgeon. The classroom format for the course is highly interactive; all sessions conclude with question/answer sessions and panel discussions. The course will be limited to 35 attendees to accommodate a didactics rotation schedule of up to 15 tables hosted by medical device and biologics companies. Cadaver labs will also be offered during the intense 21/2 day course.

Dr. Christopher L. Reeves, Program Co-chair and Faculty and Director of Research Advent Health Podiatric Surgical Residency, said he anticipates registration will fill up by mid-September. "The registration process will pick up even faster once the outgoing group of fellows and residents know their schedules and the incoming group are firmly in place."

The Lower Extremity IEP Fellows, Residents & Young Surgeons' Course is led by Dr. Gregory C. Pomeroy, Clinical Associate Professor of Surgery at the University of New England.

Magnifi Group, Inc. is a developer of a FDA-compliant eLearning platform for the medical device and biologics industries. The company also hosts the Spine IEP Live Fellows Course; the Lower Extremity IEP Live Fellows Course and the Hip and Knee IEP Live Fellows Course.

Bespa Global, LLC is dedicated to improving patient care through education and advancements in medical science. Our unique model is changing the way Medical Companies and Health Care Professionals work together to improve patient outcomes.

Learn more at: https://www.lowerextremity-iep.com/

For Additional Information Contact:

Laura McClain: lmcclain@magnifigroup.com

Chris Newell: cnewell@bespaglobal.com

*IMAGE link for media: https://www.Send2Press.com/300dpi/20-0521s2p-seal-lower-iep-300dpi.jpg

Related link: http://www.magnifigroup.com/

This news story was published by the Neotrope® News Network - all rights reserved.